Back to Search

An Open-label, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MEDI9253, a Recombinant Newcastle Disease Virus Encoding Interleukin-12, in Combination With Durvalumab in Participants With Select Advanced/Metastatic Solid Tumors


  • Protocol Number: 202008066
  • Principal Investigator: Johanns, Tanner
  • Cancer Types: Early Phase, Gastrointestinal, GU: Bladder, Kidney, Prostate, Testicular

For more information on this trial, contact us here:

Phone
800-600-3606
Email
info@ccadmin.wustl.edu

Brief Summary

Protocol Interventions